COST EFFECTIVENESS ANALYSIS EVALUATING FACTOR VIII AS PRIMARY PROPHYLAXIS TREATMENT FOR PATIENTS WITH SEVERE HAEMOPHILIA A IN THE NETHERLANDS

被引：0
|
作者：
Kip, M. [1 ]
van den Bosch, M. [2 ,3 ]
Fischer, K. [4 ]
Tamminga, R. [5 ]
Lepage-Nefkens, I [1 ]
机构：
[1] PANAXEA, Enschede, Netherlands
[2] Bayer, Mijdrecht, Netherlands
[3] Univ Med Ctr Utrecht, Van Creveldkliniek, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[5] Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1687
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY57
引用
收藏
页码：A531 / A531
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF EFTRENONACOG ALFA IN TREATMENT OF SEVERE HAEMOPHILIA B PATIENTS IN TURKEY
    Tatar, M.
    Kamaci, E.
    Alhagiri, E.
    Alghamdi, M.
    VALUE IN HEALTH, 2023, 26 (12) : S162 - S162
  • [42] Improvement of the quality of health care for children with severe haemophilia a using prophylaxis and treatment of bleeding episodes with recombinant factor VIII
    Glamocanin, S.
    Trajkova-Antevska, Z.
    Coneska, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 856 - 856
  • [43] Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors
    Kasuda, S
    Tanaka, I
    Shima, M
    Matsumoto, T
    Sakurai, Y
    Nishiya, K
    Giles, AR
    Yoshioka, A
    HAEMOPHILIA, 2004, 10 (04) : 341 - 346
  • [44] COST-EFFECTIVENESS OF RECOMBINANT FACTOR IX FC PROPHYLAXIS AND RECOMBINANT FACTOR IX ONDEMAND TREATMENT IN PATIENTS WITH HAEMOPHILIA B WITHOUT INHIBITORS
    Pochopien, M.
    Tytula, A.
    Toumi, M.
    Falk, A.
    Cioni, L.
    Hakimi, Z.
    Eriksson, D.
    VALUE IN HEALTH, 2022, 25 (12) : S73 - S74
  • [45] Cost-benefit-assessment of prophylaxis in adult patients with severe haemophilia
    Berger, K. C.
    Schopohl, D.
    Eheberg, D.
    Oldenburg, J.
    Tiede, A.
    Schramm, W.
    HAEMOPHILIA, 2014, 20 : 80 - 80
  • [46] EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY
    Pipe, Steven W.
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kavakli, Kaan
    Kiialainen, Anna
    Niggli, Markus
    Chang, Tiffany
    Lehle, Michaela
    Fijnvandraat, Karin
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 99 - 99
  • [47] Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors
    Alvarez-Roman, M. T.
    Fernandez-Bello, I.
    de la Corte-Rodriguez, H.
    Hernandez-Moreno, A. L.
    Martin-Salces, M.
    Butta-Coll, N.
    Rivas-Pollmar, M. I.
    Rivas-Munoz, S.
    Jimenez-Yuste, V.
    HAEMOPHILIA, 2017, 23 (01) : E50 - E54
  • [48] Personalized Prophylaxis with myPKFiTCE: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients
    Antonazzo, Ippazio Cosimo
    Cortesi, Paolo Angelo
    Zanon, Ezio
    Pasca, Samantha
    Morfini, Massimo
    Santoro, Cristina
    De Cristofaro, Raimondo
    Di Minno, Giovanni
    Cozzolino, Paolo
    Mantovani, Lorenzo Giovanni
    MEDICINA-LITHUANIA, 2024, 60 (01):
  • [49] COST-MINIMISATION ANALYSIS OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN VERSUS EMICIZUMAB FOR HAEMOPHILIA A PROPHYLAXIS IN EUROPE
    Hakimi, Z.
    Nazir, J.
    Pochopien, M.
    Aballea, S.
    Skrzeczek, A.
    VALUE IN HEALTH, 2020, 23 : S743 - S743
  • [50] Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan
    Liou, W. -S.
    Tu, T. -C.
    Cheng, S. -N.
    Chou, T. -Y.
    Lee, C. -F.
    Lin, T. -K.
    Chung, M. -I.
    Cham, T. -M.
    HAEMOPHILIA, 2011, 17 (01) : 45 - 54
12345